GlobeNewswire

Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal isavuconazole (Cresemba®) in Japan

Share

Basel, Switzerland, January 07, 2021

Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that patient enrolment has been completed in the phase 3 study with the antifungal isavuconazole (Cresemba®), which is conducted in Japan by Basilea’s partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma). The study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.1

David Veitch, Chief Executive Officer of Basilea, said: “The completion of patient enrolment in the phase 3 study is an important step in the development of Cresemba in Japan, where we see one of the commercially most important opportunities for the drug. Our partner Asahi Kasei Pharma expects to obtain study results in the second half of 2021, which will be the next major milestone for potentially making Cresemba available for patients in Japan.“

The partnership between Basilea and Asahi Kasei Pharma was established in September 2016. Under the terms of the agreement, Asahi Kasei Pharma was granted an exclusive license to develop and commercialize isavuconazole in Japan. Basilea received an upfront payment of CHF 7 million and will be eligible to receive up to approximately CHF 60 million of additional payments upon achievement of regulatory and commercial milestones. Basilea will also receive double-digit tiered royalties on product sales in Japan.

Cresemba has been approved in more than 50 countries to date and is currently marketed in 48 countries, including the United States, most EU member states and several additional countries inside and outside of Europe. For the twelve-month period to the end of September 2020, total "in-market" sales of Cresemba amounted to USD 244 million, a more than 28 percent growth year-on-year.2

About isavuconazole (Cresemba)

Isavuconazole is an intravenous (i.v.) and oral azole antifungal, commercialized under the trade name Cresemba. In the 27 European Union member states, as well as in Iceland, Liechtenstein, Norway and the U.K., isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate.3 Cresemba is also approved in the United States and several additional countries in Europe and beyond.4 It has orphan drug designation in the U.S., Europe and Australia for its approved indications. Basilea has entered into several license and distribution agreements for isavuconazole covering the United States, Europe, China, Japan, Latin America, Asia-Pacific, the Middle East and North Africa region, Canada, Russia, Turkey and Israel.

About invasive aspergillosis and mucormycosis

Invasive aspergillosis and mucormycosis are life-threatening fungal infections that predominantly affect immunocompromised patients, such as patients with hematologic malignancies (blood cancer). Both infections are associated with high morbidity and mortality.

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com

References

  1. Clinicaltrials.gov identifier NCT03471988
  2. IQVIA, September 2020. In-market sales reported as moving annual total (MAT) in U.S. Dollar corrected for currency fluctuations.
  3. European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu [Accessed: January 06, 2021]
  4. The registration status and approved indications may vary from country to country.

Attachment:


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Correction: CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS22.1.2021 16:43:41 CETPress release

Bid procedure, 2021-01-29BondsSWEDISH GOVERNMENT: 1053. SE0002829192. 2039-03-30 SWEDISH GOVERNMENT: 1056, SE0004517290, 2032-06-01 KINGDOM OF SWEDEN, XS2226974504, 2030-09-09 Bid date2021-01-29Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1053: 500 mln SEK +/-250 mln SEK 1056: 500 mln SEK +/-250 mln SEK XS2226974504: 250 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1053: 500 mln SEK per bid 1056: 500 mln SEK per bid XS2226974504: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-02-02Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-01-22 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English tr

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS22.1.2021 16:27:52 CETPress release

Bid procedure, 2021-01-25BillsSWEDISH T-BILL: SE0015244405. 2021-12-15 Bid date2021-01-25Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0015244405: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0015244405: 1000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-01-27Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-01-22 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS22.1.2021 16:20:00 CETPress release

Bid procedure, 2021-01-25BillsSWEDISH T-BILL: SE0015244405. 2021-12-15 Bid date2021-01-25Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0015244405: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0015244405: 1000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-01-27Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-01-22 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS22.1.2021 16:20:00 CETPress release

Bid procedure, 2021-01-29BondsSWEDISH GOVERNMENT: 1053. SE0002829192. 2039-03-30 SWEDISH GOVERNMENT: 1056, SE0004517290, 2032-06-01 KINGDOM OF SWEDEN: 144A, XS2226974413, 2030-09-09 Bid date2021-01-29Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1053: 500 mln SEK +/-250 mln SEK 1056: 500 mln SEK +/-250 mln SEK 144A: 250 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1053: 500 mln SEK per bid 1056: 500 mln SEK per bid 144A: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-02-02Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-01-22 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS22.1.2021 16:20:00 CETPress release

Anbudsförfarande kommuner och regioner, 2021-01-26BondsFixed rate notes issued in SEK by Municipalities or Regions with maturity in: 2024 The following issuers are accepted for delivery: Göteborgs Stad Helsingborgs Stad Jönköpings Kommun Malmö Stad Region Skåne Stockholms Stad Region Stockholm Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2021-01-15BidsBids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se Bid date2021-01-26Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 1000 +/- 1000 millionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 1 000 million. No bid may contain Bonds exceeding SEK 1000 million issued by the Stockh

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS22.1.2021 16:20:00 CETPress release

Bid procedure, 2021-01-28BondsSWEDBANK HYPOTEK AB: 195. SE0013546066. 2025-06-18 STADSHYPOTEK AB: 1590, SE0012676690, 2025-09-03 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 SKANDINAVISKA ENSKILDA: 580, SE0013101722, 2025-12-17 LANSFORSAKRINGAR HYPOTEK: 518, SE0011309244, 2025-09-17 DANSKE HYPOTEK AB: 2512, SE0013877214, 2025-12-17 NORDEA HYPOTEK AB: 5535, SE0013358413, 2025-09-17 Bid date2021-01-28Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)195: 1300 mln SEK +/-650 mln SEK 1590: 1500 mln SEK +/-750 mln SEK 146: 800 mln SEK +/-400 mln SEK 580: 900 mln SEK +/-450 mln SEK 518: 800 mln SEK +/-400 mln SEK 2512: 400 mln SEK +/-200 mln SEK 5535: 1300 mln SEK +/-650 mln SEK Highest permitted bid volume (corresponding nominal amount)195: 1300 mln SEK per bid 1590: 1500 mln SEK per bid 146: 800 mln SEK per bid 580: 900 mln SEK per bid 518: 800 mln SEK per bid 2512: 400 mln SEK per bid 5535: 1300 mln SEK per bid Lowest permitted bid volume

Hexagon Purus selected by New Flyer as partner for hydrogen bus market in North America22.1.2021 16:00:00 CETPress release

Hexagon Purus has entered into an agreement with North America’s largest mass mobility solutions provider, New Flyer of America Inc. and New Flyer Canada ULC (collectively “New Flyer”) for the supply of high-pressure hydrogen tanks. These tanks are destined for New Flyer’s groundbreaking zero-emission Xcelsior CHARGE H2™ hydrogen fuel cell electric transit buses in 2021. Total contract value is approximately USD 900,000 (approximately NOK 7.7 million). Driving energy transformation The hydrogen tanks, which rely upon Hexagon Purus technology, will be used to store compressed zero-emission hydrogen gas. These high-pressure tanks are certified for use in North America and Europe. The tanks will be manufactured at Hexagon Purus’ North American production facility in Taneytown, Maryland. “New Flyer and Hexagon Purus have been breaking new ground in hydrogen fuel use together since 2015,” says Harald Londer, Sales Director Hydrogen Automotive for Hexagon Purus. “Pressure containment technol